0001209191-24-004045.txt : 20240227 0001209191-24-004045.hdr.sgml : 20240227 20240227210644 ACCESSION NUMBER: 0001209191-24-004045 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240214 FILED AS OF DATE: 20240227 DATE AS OF CHANGE: 20240227 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Palmer Pamela P CENTRAL INDEX KEY: 0001511365 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35068 FILM NUMBER: 24689762 MAIL ADDRESS: STREET 1: C/O ACELRX PHARMACEUTICALS, INC. STREET 2: 351 GALVESTON DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TALPHERA, INC. CENTRAL INDEX KEY: 0001427925 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1850 GATEWAY DRIVE STREET 2: SUITE 175 CITY: SAN MATEO STATE: CA ZIP: 94404 BUSINESS PHONE: 650-216-3500 MAIL ADDRESS: STREET 1: 1850 GATEWAY DRIVE STREET 2: SUITE 175 CITY: SAN MATEO STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: ACELRX PHARMACEUTICALS INC DATE OF NAME CHANGE: 20080222 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2024-02-14 0 0001427925 TALPHERA, INC. TLPH 0001511365 Palmer Pamela P C/O TALPHERA, INC. 1850 GATEWAY DRIVE, SUITE 175 SAN MATEO CA 94404 1 1 0 0 Chief Medical Officer 0 Common Stock 2024-02-14 4 A 0 18000 0.00 A 53344 D Stock Option (Right to Buy) 1.03 2024-02-14 4 A 0 108000 0.00 A 2034-02-13 Common Stock 108000 108000 D The restricted stock units shall vest in three equal consecutive annual installments on February 14, 2025, February 14, 2026 and February 14, 2027. On February 14, 2024, the reporting person was granted an option to purchase 108,000 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods. /s/Martha Adler, Attorney-In-Fact 2024-02-27